{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-005562","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.830086+00:00","generated_at":"2026-06-18T20:53:51.424726+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corcept reports Q4 revenue $103.1M, FY 2022 revenue $401.9M; guides 2023 revenue $430-450M","bullets":["Q4 2022 revenue $103.1M vs $98.8M Q4 2021; FY revenue $401.9M vs $366.0M.","FY 2022 diluted EPS $0.87 vs $0.89 in 2021; net income $101.4M vs $112.5M.","Cash and investments $436.6M at Dec 31, 2022, up from $335.8M year-end 2021.","NDA for relacorilant in Cushing's syndrome expected Q1 2024; GRACE enrollment closing.","Phase 3 ROSELLA (ovarian cancer) and Phase 2 DAZALS (ALS) enrolling; miricorilant Phase 1b NASH data mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-005562","json":"https://secwatch.observer/filing/0001628280-23-005562.json","markdown":"https://secwatch.observer/filing/0001628280-23-005562.md","text":"https://secwatch.observer/filing/0001628280-23-005562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/0001628280-23-005562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/cort-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:53:51.424726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90a5ca0e207bc72e5a312ce0bcb1962ee793826f","claim":"CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2022 results: revenue $103.1 million, net income $16.6 million, EPS $0.14 per diluted common share. Guidance reaffirmed.","evidence_excerpt":"Fourth quarter revenue of $103.1 million, compared to $98.8 million in fourth quarter 2021 • 2022 revenue of $401.9 million, compared to $366.0 million in 2021 • 2023 revenue guidance of $430 – $450 million • Fourth quarter diluted net income per common share of $0.14, compared to $0.26 in fourth quarter 2021 • 2022 diluted net income per common share of $0.87, compared to $0.89 in 2021 • Cash and investments of $436.6 million, compared to $335.8 million at December 31, 2021 Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 million. Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021. For the full year, it was $101.4 million compared to $112.5 million in 2021. Cash and investments of $436.6 million at December 31, 2022 compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/0001628280-23-005562-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$103.1 million"},{"label":"Net income","value":"$16.6 million"},{"label":"EPS","value":"$0.14 per diluted common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}